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Personalized medicationAbstract Variations in drug metabolism may alter drug efficacy and cause toxicity; better understanding
of the mechanisms and risks shall help to practice precision medicine. At the 21st International
Symposium on Microsomes and Drug Oxidations held in Davis, California, USA, in October 2–6,
2016, a number of speakers reported some new findings and ongoing studies on the regulation
mechanisms behind variable drug metabolism and toxicity, and discussed potential implications to
personalized medications. A considerably insightful overview was provided on genetic and epigenetic
regulation of gene expression involved in drug absorption, distribution, metabolism, and excre-
tion (ADME) and drug response. Altered drug metabolism and disposition as well as molecular
mechanisms among diseased and special populations were presented. In addition, the roles of gut
microbiota in drug metabolism and toxicology as well as long non-coding RNAs in liver functions and
diseases were discussed. These findings may offer new insights into improved understanding of ADME
regulatory mechanisms and advance drug metabolism research.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Efficacy and safety are two elements that determine the utility of a
therapeutic drug for the treatment of a particular disease. Drug
efficacy and safety profiles are governed by how the drug interacts
with on-target and off-target molecules. Furthermore, how the drug
is processed in the body will inevitably affect the accessibility of
drug to its targets, by which the former consists of a number of
critical processes namely absorption, distribution, metabolism and
excretion (ADME). Mechanistically, drug-metabolizing enzymes
and transporters (DMET) are the molecular determinants of the
ADME processes. Therefore, pharmaco-/toxico-kinetic properties
of a drug, such as bioavailability, half-life and exposure, are
dictated by the interactions of the drug with DMETs, which will
ultimately determine drug efficacy and safety profiles following
their actions on targets.
Variations in drug ADME or pharmacokinetics are common
among a defined population as well as various groups, which may
alter drug efficacy or cause toxicity1–3. Indeed, the inhibition or
activation of DMET protein functions often leads to remarkable
variations in pharmacokinetics and consequently drug efficacy or
toxicity. Secondly, changes in transcriptional gene expression of
DMETs, which are governed by xenobiotic receptors or transcrip-
tion factors in cells, have been revealed as another major cause of
variations in drug metabolism and toxicity. Thirdly, genetic
variations of ADME genes could lead to significant changes in
DMET expression or activity in the metabolism and transport of
drugs. In addition, recent studies have demonstrated that many
other factors such as epigenetics, noncoding RNAs (ncRNAs), and
gut microbiota4–9 may modulate ADME gene expression and
cause variations in drug metabolism and toxicity.
The International Symposia on Microsomes and Drug Oxida-
tions (MDO) are a well known series of conferences in the field of
drug metabolism and related areas (https://mdo.ki.se/). The 21st
MDO conference was held in Davis, California, USA, in October
2–6, 2016, to provide a unique opportunity for investigators and
scientists to interact with each other. The programs consisted of
1 keynote lecture, 4 plenary lectures, 24 parallel sessions, and 120
posters. With a focus on the most recent advances in the fields of
drug metabolism, the programs covered a wide range of importanttopics, including DMET structure and function, ADME gene
regulation, drug development, and clinical pharmacology and
toxicology. Some new merging fields, such as gene editing, gut
microbiota, metabolomics, and lncRNAs, were also included. This
report is to summarize some talks presented at the 21st MDO
conference that are related to the regulation of drug metabolism
and toxicity, particularly by multiple factors of genetics, epige
netics, lncRNAs, gut microbiota, and diseases.2. Plenary lecture on “genetic and epigenetic regulation of
ADME gene expression and drug response” by Dr. Magnus
Ingelman-Sundberg
Dr. Ingelman-Sundberg started off by reviewing the current
important pharmacogenomic biomarkers used in clinical medicine
and in guidance by European Medicines Agency (EMA) and The
US Food and Drug Administration (FDA). About 15% of medical
products approved by EMA and 138 medicines approved by FDA
contain pharmacogenomic labels. The most important pharmaco-
genomic biomarkers are related to genes encoding HLA mole-
cules, enzymes, transporters, drug targets, specific markers and
mutations in the somatic genome where mutations in the genes of
ABL, ALK, BRAF, EGRF, HER2, KRAS, KIT, and MET are of
importance for selection of anticancer therapy.
Dr. Ingelman-Sundberg then explained the developmental origin
of human polymorphisms. He pointed out genetic drift and genetic
selection as the most important bases for the occurrence of today's
polymorphism. He gave examples of genetic selection from the
animal world where tolerance to new environments has been
developed through selection for CYP gene inducibility, expression
and substrate specificities. They are exemplified, e.g., by the
microsatellite 100-fold amplification of CYP6CY3 in Myzus persicae
as adaptation for the tobacco plant as host, since the corresponding
enzyme is active in nicotine metabolism. The genetic selection was
also exemplified comparing the difference between mice and humans
in alkaloid detoxification as well as the evolution of the CYP2D6
duplication in North East Africa.
Dr. Ingelman-Sundberg further presented the €15 million
Ubiquitous Pharmacogenomics project (http://upgx.eu/) that will
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Pharmacotherapy of 8000 patients in 7 different clinical centers
will either be based on pharmacogenetic parameters or conducted
in the standard mode for 18 months each. In addition, outliers will
be more thoroughly analyzed using next generation sequencing.
Dr. Ingelman-Sundberg then discussed at length the influence of
rare mutations on drug pharmacokinetics and effects. He con-
cluded that rare mutations might be absent in some populations but
indeed common in specific geographical regions as exemplified by
CYP3A4*20 which is only expressed in some parts of Spain, and is
important for, e.g., paclitaxel treatment regimen in carriers of this
allele. He presented data from several papers where they had
presented the number and types of rare mutations in 57 P450
genes and 146 genes encoding other phase I, phase II enzymes,
transporters, and nuclear receptors mainly from human exome data
bases. He concluded that as a whole the number of variants per kb
gene was similar among transporters and phase II enzymes, but
that severe differences exist in the number of rare mutations in
different genes. Thus among the ABC transporter family, the
ABCA4 gene carried 370 variant alleles, whereas only 40 variant
alleles were identified in the ABCB7 gene. Similar differences
occurred in the other classes of ADME genes analyzed. He
presented data regarding the contribution of rare alleles to the
overall fractional variability of different genes and concluded that
in many genes the role of rare variants is very high. Among the
P450 genes, CYP1A2, CYP2A6, CYP2C19, and CYP3A4
genes have a high contribution of rare alleles to the genetic
variations and overall it can be calculated that the rare variants
contribute to 30%–40% of the inherited variability in drug
pharmacokinetics.
He reviewed data from the ExAc project10, analyzing the exomes
from 60,706 humans where they conclude that in the exomes each 8th
nucleotide is subject to polymorphism and that 55% of all 7.5 million
mutations identified were present as singletons. He reviewed results
by Kerb and Schwab11 from twins studies showing that only 40% of
the genetic variability of the pharmacokinetics of torsemide or
metoprolol can be explained by known polymorphisms. He con-
cluded that overall both the analyses of different rare mutations in the
different ADME genes and the results from the twin studies indeed
indicate that by using standard analyses for polymorphic genes only
50%–60% of the true genetic variation can be identified. He
elaborated how this information will influence future pharmacoge-
netic testing of patients.
Dr. Ingelman-Sundberg then presented his laboratory's novel
system for culturing viable liver cells for 5 weeks in a 3D spheroid
system12. The proteome of the spheroid to a great extent mimic the
proteome in the liver from where they were isolated, whereas cells
cultivated in 2D had a very different proteome. In the spheroid
system it was thus possible to study true inter-individual variation.
He presented the use of this system in in vitro disease models
including steatosis and cholestasis. It was also shown that non-
parenchymal cells integrated well in the 3D spheroids for long
periods of time and resulted in higher responsivity to pro-
inflammatory stimuli, e.g. lipopolysaccharide (LPS). Dr. Ingel-
man-Sundberg laboratory's data indicate that the spheroid system
is very suitable for analyzing chronic drug toxicity in many cases.
Dr. Ingelman-Sundberg ended his lecture by presenting data
from single nucleotide resolution analyses of ADME genes in
human liver13 and could conclude that 5 hmC is very important in
liver and that the bisulfite method does not provide a true
epigenetic analyses. Furthermore, the data revealed that ADME
gene expression is related to the overall presence of 5 mC and5 hmC in the open reading frame of the gene, but not by specific
elements with altered composition of 5 mC and 5 hmC.3. Parallel session on “disease effect on drug metabolism and
disposition”, chaired by Drs. Wen Xie and Lauren M.
Aleksunes
3.1. Regulation of drug transporters and drug disposition by
fatty liver disease, Nathan J. Cherrington from University of
Arizona, USA
Numerous drug-induced and environmental exposure–related toxi-
cities are the result of inter-individual variations in the ADME
processes of absorption, distribution, metabolism, and elimination
that control the fate of these compounds from the body. Alterations
in these processes provide the mechanistic basis for individual
variability in response to drugs and environmental exposures. A
common perception is that variability in response is due to genetic
polymorphisms within the drug metabolizing enzyme and trans-
porter genes. While there are numerous examples of these
differences that play a major role in the susceptibility of genetic
subpopulations for specific toxicities, the potential for transient
phenotypic conversion due to temporary environmental changes,
such as inflammation and diseases, are often overlooked. Due to
the ensuing liver damage caused by the progressive stages of non-
alcoholic fatty liver disease (NAFLD), gene expression patterns
can change dramatically resulting in a phenoconversion resem-
bling genetic polymorphisms. Because the liver plays such a key
role in the metabolism and disposition of xenobiotics, it is well
recognized that liver diseases can alter drug disposition and require
dose adjustment to maintain drug concentrations within the
therapeutic window. This temporary phenoconversion could lead
to the inability of patients to properly metabolize and excrete drugs
and environmental toxicants, increasing the risk of some adverse
drug reactions and environmental toxicities. Dr. Cherrington's
laboratory has made significant strides in identifying liver-specific
disturbances in the expression and function of xenobiotic bio-
transformation enzymes and membrane drug transporters. Impor-
tantly, these molecular alterations in the expression and functions
of drug transporters and biotransformation enzymes lead to in vivo
perturbations in the disposition of numerous xenobiotics. There-
fore, Dr. Cherrington suggests that patients with NAFLD present
as a subpopulation of individuals that are at higher risk for
developing adverse drug reactions, due to aberrant disposition of
drugs and other xenobiotics. Specifically, Dr. Cherrington's
laboratory has documented individual differences in ADME
genes and proteins, such as metabolizing enzymes and transporters
that cause a profound alteration in the pharmacokinetics,
overall exposure, and toxicity of clinically relevant drugs and
xenobiotics.
3.2. Endobiotic and xenobiotic disposition in pregnancy and
maternal cholestasis, Lauren M. Aleksumes from Rutgers
University, USA
Pregnancy is a critical period with high nutritional demands in
order to support fetal growth and development. To accommodate
these needs, the enterohepatic, renal, and cardiovascular systems
undergo a number of adaptive molecular and physiological
changes. Circulating hormones and growth factors modify global
transcription factor signaling and drug disposition. Dr. Aleksunes
Ai-Ming Yu et al.244described adaptive changes in the expression of drug and bile acid
metabolizing enzymes as well as transporters in pregnant mice14–18.
To enhance the absorption of lipids during pregnancy, bile acid
synthesis is increased and transport is reduced16. An enhanced
supply of bile acids coupled with reduced enterohepatic circulation
predisposes pregnant women to develop intrahepatic cholestasis.
Interestingly, in pregnancy, Aleksunes demonstrated a down-
regulation of the fibroblast growth factor 15 (mice)/19 (human),
an ileal endocrine factor that represses hepatic bile acid synth-
esis19. Ex vivo studies using primary hepatocytes and serum from
pregnant mice further supports the critical role of circulating
hormones as modulators of the classic bile acid synthesis enzyme,
CYP7A1. Treatment with recombinant FGF19 restored the expres-
sion of Cyp7a1 in primary hepatocytes cultured with serum from
pregnant mice19. Additional data pointed to a potential role for
17β-estradiol to down-regulate FGF19 in cultured human intestinal
cells primed with the bile acid, chenodeoxycholic acid. Using
pharmacological activators of the farnesoid X receptor GW4064
and the constitutive androstane receptor TCPOBOP, the Aleksunes
laboratory has demonstrated restored expression of bile acid
and drug metabolizing enzyme and transporter pathways in the
livers and intestines of pregnant mice19. These data point to a
novel pharmacological approach to regulate liver–intestine bile
acid crosstalk during pregnancies complicated by maternal
cholestasis.3.3. Role of nuclear receptors and microRNAs in the regulation
of drug metabolism by inflammation, Ulrich M. Zanger from Dr.
Margarete Fischer-Bosch-Institute of Clinical Pharmacology,
Germany
Variability in drug response is caused by various genetic and
nongenetic factors20. Data from the genome-wide expression studies
in human liver (n¼150) from Dr. Zanger's laboratory21 show that the
clinical inflammation marker C-reactive protein (CRP) is associated
with a broad “negative acute phase response” that comprises most
drug metabolizing enzymes and transporters (DMET), supporting a
well-documented negative influence of inflammation on drug meta-
bolism22. To investigate mechanisms leading to coordinated DMET
downregulation, Dr. Zanger's laboratory treated human primary
hepatocytes (PHH) with IL-6 and selective signal transduction
inhibitors. Reverse-phase phosphoproteomics analysis suggested a
more important role of MAPK and PI3K over JAK/STAT signaling
for DMET regulation. Mathematical modeling using fuzzy-logics and
extensive time-resolved data from five liver donors suggested a
central role of heterodimeric RXRα/nuclear receptor complexes to
coordinately downregulate most DMET genes, which was confirmed
by siRNA-mediated knock-down in PHH23. Zanger's laboratory also
observed a significant downregulation of RXRα protein but not its
transcript in response to IL-6 and therefore investigated a possible
contribution of microRNAs. They identified numerous miRNAs
strongly elevated in cholestatic liver and during inflammation, of
which miR-130b was previously shown to downregulate various
cytochromes P450 enzyme activities and to directly target CYP2C924.
Preliminary data indicate that miR-130b also directly targets RXRα.
Taken together, the data indicate that coordinated downregulation of
DMET genes in hepatocytes in inflammatory conditions involves IL-
6 activated MAPK and PI3K signaling and inactivation or down-
regulation of RXRα/nuclear receptor complexes. MiR-130b
appears to play a role in downregulating RXRα and certain
cytochrome P450s.3.4. Regulation of sulfotransferase by local and systemic liver
injuries, Wen Xie from University of Pittsburgh, USA
Sulfotransferases are phase II drug-metabolizing enzymes (DMEs)
that play critical roles in maintaining the chemical and functional
homeostasis of xenobiotics and endobiotics. In the case of estrogen
homeostasis, estrogens can be sulfated and deactivated by the
estrogen sulfotransferase (EST, or SULT1E1), because estrogen
sulfates cannot bind to the estrogen receptor and thus are
hormonally inactive25. Accumulating evidence suggests that many
hepatic and systemic diseases can affect drug metabolism and
disposition by regulating the hepatic expression and/or activity of
DMEs and transporters, including the sulfotransferases26. This
presentation focused on the recent progress in describing and
understanding the hepatic injury and sepsis responsive regulation
of sulfotransferases in animal models. Liver ischemia and reperfu-
sion (I/R) were used as a typical model of hepatic injury, whereas
LPS and cecal ligation and puncture (CLP) were used as the sepsis
models. Dr. Xie's laboratory showed that the hepatic expression
and activity of EST was markedly induced in a mouse model of I/
R, which was associated with a higher level of estrone sulfate and
decreased expression of estrogen responsive genes in the liver in a
EST-dependent manner27. The up-regulation of EST in the liver
may have played a pathogenic role in I/R injury, because EST
ablation in female mice attenuated I/R responsive liver injury.
Interestingly, the effect of EST ablation was sex specific, because
the EST / male mice exhibited heightened I/R injury. The
gender specific role of EST in I/R injury remains to be better
understood. In an independent study, they showed that sepsis
induced the expression of EST and compromised the activity of
estrogen in the liver28. The sepsis responsive induction of EST in
the liver may have played a protective role, because EST ablation
sensitized mice to sepsis-induced death, which was recapitulated in
wild-type mice pre-treated with triclosan, a pharmacological
inhibitor of EST29. Mechanistically, Xie's laboratory showed that
EST ablation attenuated sepsis-induced inflammatory responses
due to compromised estrogen deactivation, leading to an increased
sepsis lethality. It is hoped that understanding the disease effect on
drug metabolism will facilitate the efficient and safe use
of drugs in the clinic. In the meantime, DMEs such as sulfo-
transferases may be therapeutic targets that can affect the outcome
of the diseases26.4. Parallel session on “role of gut microbiota in drug
metabolism and toxicology”, chaired by Drs. Hyunyoung
Jeong and Edward T. Morgan
4.1. The microbial pharmacists within us, Peter J. Turnbaugh
from University of California at San Francisco, USA
Large inter-individual variability in drug response has been a
major limiting factor for achieving optimal drug therapy. The
important role of the intestinal microbiota in drug metabolism has
been known since the discovery by Domagk of the antibacterial
activity of prontosil, and the subsequent determination of its
activation to sulfanilamide30. However, the roles of the micro-
biome in modern pharmacology, drug metabolism and toxicology
are underappreciated. Dr. Turnbaugh's laboratory is pursuing a
more comprehensive view of pharmacology that includes the
structure and activity of the resident microbial communities in
the human gut and a deeper understanding of their interactions
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milieu of the gastrointestinal (GI) tract. More than 50 drugs are
known to be metabolized by the microbiome, mostly by reductions
and hydrolyses31. Many of the hydrolytic reactions provide the
bacteria with nutritional substrates. One important such drug is
digoxin, which is reduced by the Actinobacteria Eggerthalla lenta
to pharmacologically inactive dihydrodigoxin. About 10% of
individuals taking digoxin excrete large amounts of dihydrodi-
goxin. The enzymes responsible have been identified as products
of the bacterial cardiac glycoside reductase Cgr operon, Cgr1 and
Cgr232. Only a subset of E. lenta strains encode the Cgr operon
and are thus able to metabolize digoxin. The abundance of the Cgr
operon in the human gut microbiota was shown to be predictive of
the inter-individual differences in digoxin inactivation using an
ex vivo assay. Cgr expression and function are inhibited by
arginine. Studies in germ-free mice colonized with wild-type E.
lenta suggested that dietary protein reduced the inactivation of
digoxin, via increasing the luminal concentration of arginine,
resulting in a significant increase in digoxin bioavailability.
These results demonstrate the interplay between strain-level
differences in the gut microbiota and dietary intake in modulating
drug disposition and thus drug response. Dr. Turnbaugh's
laboratory is continuing to study the molecular mechanisms
responsible for digoxin reduction and using this proof-of-principle
to inform the study of other drugs that are metabolized by gut
microbes.4.2. RNA-Seq quantification of hepatic drug-processing genes in
germ-free mice, Curtis D. Klaassen from University of
Washington, USA
Dr. Klaassen's presentation focused on the effect of intestinal
bacteria on the expression of hepatic drug-processing genes in the
host. RNA sequencing (RNA-Seq) was used to profile drug
metabolizing enzymes and transporters in germ-free (GF) and
conventional (CONV) mice, as well as in GF mice treated with
probiotics (i.e., bifidobacterium and lactobacillus, VSL3)33,34. In
the livers of GF mice, a number of cytochrome P450 mRNAs were
increased as compared to those in CONV mice, including Cyp1a2,
2c54, 2e1 and 4a10. Consistent with the increases in Cyp1a2 and
Cyp4a10, mRNA levels of the aryl hydrocarbon receptor and
peroxisome proliferator–activated receptor α were also up-regu-
lated in GF mice. Cy3a11 mRNA was markedly reduced by 87%,
and Cyp2b10 was decreased by 57%. However, the expression of
constitutive androstane receptor (CAR) or pregnane X receptor
(PXR) did not decrease in GF mice. Non-P450 phase I enzymes in
the livers of GF mice were only moderately affected. Glutathione
S-transferase enzymes p1 and p2 were down-regulated whereas
sulfotransferases Sult1a1 and 1d7 were induced in GF mice. A
number of solute carrier and ATP-binding cassette transporters
were up-regulated. Speculatively, the observed differences in GF
mice may be due to production of endogenous ligands of nuclear
receptors (e.g., secondary bile acids) by the microbiota, but this
has yet to be determined. In general, smaller effects were seen in
the intestines than in livers of GF mice, although Cyp3a subfamily
transcripts were down-regulated in the intestine. Administration of
probiotics to GF mice had little effect, whereas housing GF mice
with CONV mice reversed the observed effects. Overall, it is clear
that intestinal bacteria can affect drug metabolism and transport,
and are likely to be responsible for some individual differences in
drug responses.4.3. Drugging the microbiome, Aadra P. Bhatt and Mathew R.
Redinbo from University of North Carolina at Chapel Hill,
USA
Glucuronide metabolites of drugs are hydrolyzed by intestinal β-
glucuronidase (GUS) enzymes, with the glucuronide moiety
feeding in to the microbial citric acid cycle. This can lead to long
half-lives of drugs due to enterohepatic circulation, and in the case
of the anticancer drug irinotecan and non-steroidal anti-inflamma-
tory drug (NSAIDs), to gastrointestinal toxicity in the form of
severe diarrhea or ulcerations, respectively. Irinotecan is converted
to bioactive SN-38 by carboxylesterases in the body, which is
subsequently glucuronidated and excreted to the small intestine via
bile. Hydrolysis of the nontoxic SN-38 glucuronide metabolite by
the microbiota GUS enzymes leads to the release of SN-38 in the
gut and subsequent related toxicity. These bacterial enzymes thus
present a therapeutic target to reduce irinotecan toxicity via
inhibition of SN-38 glucuronide hydrolysis. Dr. Redinbo's labor-
tory used crystal structures of bacterial GUS enzymes to elucidate
the enzymatic mechanism, and identified potent and bacteria-
selective inhibitors of these enzymes by high-throughput screen-
ing35. In a mouse xenograft model, one such inhibitor did not alter
the efficacy of irinotecan in reducing tumor growth, but did
prevent irinotecan-induced toxicity (e.g., weight loss) in the mice.
GUS inhibition also reduced the formation of intestinal
ulcers in mice treated with diclofenac, which is also due to
hydrolysis of its glucuronide in the intestine36. The current
inhibitors have been developed with a focus on the Escherichia
coli enzyme, but Dr. Redinbo's laboratory is examining the
diversity of GUS enzymes in the GI microbiota. While this
illustrates the challenges of developing drugs to related microbial
targets whose representation may differ greatly among individuals,
the study underscores the enzymes in the GI microbiota as
potential drug targets that can be manipulated to achieve optimal
drug responses.5. Parallel session on “roles of long non-coding RNAs in liver
development, functions, and diseases”, chaired by Drs. Xiao-bo
Zhong and Li Wang
5.1. Non-coding RNAs and hepatic responses to drugs,
environmental chemicals, and endogenous hormones, Pengying
Hao, Tisha Melia, Nicholas J. Lodato, and David J. Waxman from
Boston University, USA
The liver responds to both xenobiotic and hormonal stimulation
with dynamic changes in gene expression and the epigenetic
landscape. Some of these responses may involve the action of long
non-coding RNAs (lncRNAs), which are increasingly recognized
as potential chromatin regulators, as well as microRNAs, which
are important post-transcriptional regulators. In work presented by
David Waxman's laboratory, non-coding RNA dynamics in liver
was examined under diverse conditions, including: (1) exposure to
TCPOBOP, an agonist ligand of the nuclear receptor CAR,
representing short-term liver responses to environmental chemical
exposure; and (2) stimulation of the liver by plasma growth
hormone, whose sex-differential pituitary secretion pattern imparts
widespread hepatic sex-differences37. First, they used a stringent
computational discovery pipeline38 to identify 15,558 mouse liver-
expressed lncRNAs, based on an analysis of a diverse set of 186
mouse liver RNA-seq datasets, representing 30 biological
Ai-Ming Yu et al.246conditions. Strikingly, they found that liver-expressed lncRNA
gene promoters show greater species conservation and a higher
frequency of proximal binding by liver transcription factors than
corresponding protein-coding gene promoters. Further, activation
of the nuclear receptor CAR in mouse liver (TCPOBOP treatment
for 3–27 h) was found to significantly alter the expression of 166
lncRNAs. Many of these lncRNAs are intragenic or transcribed
anti-sense to CAR-regulated CYP genes and genes that encode
other drug-metabolizing enzyme RNAs, suggesting their co-
regulation. Comparing the male and female liver transcriptome,
they identified 247 lncRNAs showing strong sex bias and tight
regulation by growth hormone38, with significant enrichment for
nearby growth hormone-regulated DNase hypersensitive sites39
and sex-dependent binding sites for growth hormone-regulated
transcription factors such as STAT540 and HNF641. In other
studies, the Waxman laboratory investigated the role of micro-
RNAs in liver sex differences, and identified 13 sex-biased liver
microRNAs by small RNA sequencing. Two of these microRNAs
were found to be tightly regulated by the transcription
factor STAT5 following its activation by growth hormone. To
assess functionality, one of the male-specific miRNAs was over-
expressed in female mouse liver using adenovirus, which led to
widespread gene expression changes in liver. This work leverages
deep sequencing and integrative data analyses to elucidate
exogenous and endogenous stimuli-induced liver transcriptome
dynamics.5.2. LncRNAs in liver metabolic functions, Li Wang from
University of Connecticut, USA
Dr. Li Wang reported a novel function of lncRNA MEG3 in bile
acid homeostasis and cholestatic liver injury. Bile acids play
critical physiological functions in cholesterol homeostasis and
deregulation of bile acid metabolism causes cholestatic liver
injury. Maternally expressed gene 3 (MEG3) was recently shown
as a potential tumor suppressor; however, its basic hepatic function
remains elusive. Using RNA pull-down with biotin-labeled sense
or anti-sense MEG3 RNA followed by mass spectrometry, Dr.
Wang's laboratory identified RNA binding protein polypyrimidine
tract-binding protein 1 (PTBP1) as a MEG3 interaction protein and
validated their interaction by RNA immunoprecipitation (RIP).
Bioinformatics analysis revealed putative binding sites for PTBP1
within the coding region (CDS) of small heterodimer partner
(SHP); a key repressor of bile acid biosynthesis. Forced expression
of MEG3 in hepatocellular carcinoma (HCC) cells guided and
facilitated PTBP1 binding to Shp CDS, resulting in Shp mRNA
decay. Transient overexpression of MEG3 RNA in vivo in mouse
liver caused rapid Shp mRNA degradation and cholestatic liver
injury, which was accompanied by the disruption of bile acid
homeostasis, elevation of liver enzymes, and dysregulation of bile
acid synthetic enzymes and metabolic genes. Interestingly, RNA-
seq coupled with qPCR revealed a drastic induction Meg3 RNA in
Shp–/– liver. SHP inhibited MEG3 gene transcription by repressing
cAMP response element-binding protein (CREB) transactivation
of the MEG3 promoter. In addition, the expression of MEG3 and
PTBP1 was activated in human fibrotic and NASH cirrhotic liver.
At the end of the presentation, Dr. Wang concludes that MEG3
causes cholestasis by destabilizing Shp via serving as a guide RNA
scaffold to recruit PTBP1 to Shp mRNA. SHP in turn represses
CREB-mediated activation of MEG3 expression in a feedback
regulatory fashion.5.3. Role of lncRNAs in postnatal liver maturation, Chad Pope
and Xiao-bo Zhong from University of Connecticut, USA
The adult liver conducts critical functions in metabolism of various
endogenous and exogenous compounds, including drugs. How-
ever, the functions are not mature yet in liver at neonatal and infant
ages. There is a postnatal maturation process in liver to reflect a
functional transition, in which the molecular mechanisms control-
ling the process have not been fully established. LncRNAs have
been implicated to play important roles in organ development and
cell proliferation. Dr. Zhong presented an initial study to establish
the role of lncRNAs in postnatal liver maturation in a mouse
model. In a preliminary screening42, Dr. Zhong's laboratory
applied RNA-Seq to examine ontogeny of all annotated lncRNAs
in mouse liver during postnatal maturation from perinatal (day
2) to adult (day 60). They found nearly 2000 lncRNAs were
differentially expressed in liver during liver maturation. In general,
lncRNAs were expressed at a lower level than the coding mRNAs.
Both coding mRNAs and lncRNAs displayed three major onto-
genic patterns with a similar proportion among the neonatal,
adolescent, or adult enriched patterns. Closed neighboring pairs of
coding mRNAs and lncRNAs showed the trend to exhibit highly
correlated ontogenic expression patterns, indicating that lncRNAs
may share similar regulatory mechanisms with their cis-coding
genes in same chromatin segments. In a comparison with the
previously deciphered developmental dynamics of the mouse liver
transcriptome of all coding mRNAs43, gene ontology (GO)
analysis revealed that some lncRNAs enriched at neonatal ages
had their neighbor protein-coding genes also enriched at neonatal
ages and functions of those proteins were associated with liver
growth, immune activation related processes, cell proliferation,
tissue organization, and hematopoiesis. Some other lncRNAs
enriched at adult ages had their neighboring protein-coding genes
associated with different metabolic functions.
Dr. Zhong's laboratory further identified 433 pairs of such
lncRNAs and coding mRNAs, in which lncRNAs were signifi-
cantly differentially expressed during postnatal liver maturation
and their neighboring protein-coding genes were also expressed in
the same ontogenic patterns. Several top candidate lncRNAs in the
list were selected for further validation. One of the selected
lncRNAs is H19, a lncRNA located in a genomic imprinting
region differentially expressed in liver regulated by a DNA
methylated region on maternal and paternal chromosomes. At
the end of the presentation, Dr. Zhong described an experimental
design to use a genetic modified mouse strain with a deletion of
H19 on the maternal chromosome to further investigate the role of
H19 in liver postnatal maturation.6. Summary
A number of talks presented at the 21st MDO conference have
overviewed recent important findings on the effects on drug
metabolism and toxicity by multiple factors of genetics, epige-
netics, lncRNAs, gut microbiota, and diseases. The programs
nicely covered both traditional and rising topics in drug metabo-
lism and related areas. These exceptional presentations, following
questions, and insightful discussions shall undoubtedly stimulate
further studies on the regulatory mechanisms underlying variable
drug metabolism and toxicity, which will ultimately advance the
field of drug metabolism.
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